The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth invitro without light activation

Experimental Eye Research

Volumn 124, Issue , 2014, Pages 67-73

  Brodowska, Katarzyna ^a   Al Moujahed, Ahmad ^a   Marmalidou, Anna ^a   Meyer zu Horste, Melissa ^a   Cichy, Joanna ^b   Miller, Joan W ^a   Gragoudas, Evangelos ^a   Vavvas, Demetrios G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Cancer; Eye; Hippo; Intraocular; Oct4; YAP

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; CYSTEINE RICH PROTEIN 61; MAMMALIAN TARGET OF RAPAMYCIN; OCTAMER TRANSCRIPTION FACTOR 4; TEAD TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN A; VERTEPORFIN; YES ASSOCIATED PROTEIN;

ANGIOGENESIS; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CELL CYCLE PHASE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGHT; ONCOGENE C MYC; PRIORITY JOURNAL; PROTO ONCOGENE; RETINOBLASTOMA; RETINOBLASTOMA CELL LINE;

CANCER; EYE; HIPPO; INTRAOCULAR; OCT4; YAP;

CELL PROLIFERATION; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RETINA; RETINAL NEOPLASMS; RETINOBLASTOMA; TUMOR CELLS, CULTURED;

EID: 84901490516     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2014.04.011     Document Type: Article

References (60)

1. Agostinis P., Berg K., Cengel K.A., Foster T.H., Girotti A.W., Gollnick S.O., Hahn S.M., Hamblin M.R., Juzeniene A., Kessel D., et al. Photodynamic therapy of cancer: an update. CA: Cancer J. Clin. 2011, 61:250-281.
2. Bellou S., Pentheroudakis G., Murphy C., Fotsis T. Anti-angiogenesis in cancer therapy: Hercules and hydra. Cancer Lett. 2013, 338:219-228.
3. Benz M.S.M., Scott I.U.I., Murray T.G.T., Kramer D.D., Toledano S.S. Complications of systemic chemotherapy as treatment of retinoblastoma. Arch. Ophthalmol. 2000, 118:577-578.
4. Bianciotto C., Shields C.L., Iturralde J.C., Sarici A., Jabbour P., Shields J.A. Fluorescein angiographic findings after intra-arterial chemotherapy for retinoblastoma. Ophthalmol. 2012, 119:843-849.
5. Brancho D., Tanaka N., Jaeschke A., Ventura J.-J., Kelkar N., Tanaka Y., Kyuuma M., Takeshita T., Flavell R.A., Davis R.J. Mechanism of p38 MAP kinase activation invivo. Genes. Dev. 2003, 17:1969-1978.
6. Broaddus E., Topham A., Singh A.D. Incidence of retinoblastoma in the USA: 1975-2004. Br. J. Ophthalmol. 2009, 93:21-23.
7. Carracedo A., Baselga J., Pandolfi P.P. Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell. Cycle 2008, 7:3805-3809.
8. Celli J.P., Solban N., Liang A., Pereira S.P., Hasan T. Verteporfin-based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines. Lasers Surg. Med. 2011, 43:565-574.
9. Chen P.-X., Li Q.-Y., Yang Z. Axl and prostasin are biomarkers for prognosis of ovarian adenocarcinoma. Ann. Diagn. Pathol 2013, 17(5):425-429.
10. Cicenas J. The potential role of Akt phosphorylation in human cancers. Int. J. Biol. Markers 2008, 23(1):1-9.
11. Coumar M.S., Tsai F.-Y., Kanwar J.R., Sarvagalla S., Cheung C.H.A. Treat cancers by targeting survivin: just a dream or future reality?. Cancer Treat. Rev. 2013, 39:802-811.
12. Ewald F., Grabinski N., Grottke A., Windhorst S., Nörz D., Carstensen L., Staufer K., Hofmann B.T., Diehl F., David K., et al. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. Int. J. Cancer 2013, 133:2065-2076.
13. Fernandez-L A., Squatrito M., Northcott P., Awan A., Holland E.C., Taylor M.D., Nahlé Z., Kenney A.M. Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation. Oncogene 2012, 31:1923-1937.
14. García-Fernández L.F., Losada A., Alcaide V., Alvarez A.M., Cuadrado A., González L., Nakayama K., Nakayama K.I., Fernández-Sousa J.M., Muñoz A., et al. Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta. Oncogene 2002, 21:7533-7544.
15. Gartel A.L. p21(WAF1/CIP1) and cancer: a shifting paradigm?. Biofactors 2009, 35:161-164.
16. Gartel A.L., Radhakrishnan S.K. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 2005, 65:3980-3985.
17. Ghassemi F., Shields C.L. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch. Ophthalmol. 2012, 130:1268-1271.
18. Gu Z., Zhang F., Wang Z.-Q., Ma W., Davis R.E., Wang Z. The p44/wdr77-dependent cellular proliferation process during lung development is reactivated in lung cancer. Oncogene 2013, 32(15):1888-1900.
19. Harbour J.W. Photodynamic therapy for choroidal metastasis from Carcinoid tumor. Am. J. Ophthalmol. 2004, 1143-1145.
20. Hu H., Deng F., Liu Y., Chen M., Zhang X., Sun X., Dong Z., Liu X., Ge J. Characterization and retinal neuron differentiation of WERI-Rb1 cancer stem cells. Mol. Vis. 2012, 18:2388-2397. Epub 2012 Sep. 24.
21. Husain D., Kramer M., Kenny A.G., Michaud N., Flotte T.J., Gragoudas E.S., Miller J.W. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. IOVS 1999 Sep, 40(10):2322-2331. PMID: 10476799.
22. Isola V., Pece A., Pierro L. Photodynamic Therapy with Verteporfin of Choroidal Malignancy from Breast Cancer 2006, 1-3.
23. Kessel D., Vicente M.G.H., Reiners J.J. Initiation of apoptosis and autophagy by photodynamic therapy. Lasers Surg. Med. 2006, 38:482-488.
24. Kondo Y., Kanzawa T., Sawaya R., Kondo S. The role of autophagy in cancer development and response to therapy. Nat. Rev. Cancer 2005, 5:726-734.
25. Lee K.-B., Byun H.-J., Park S.H., Park C.-Y., Lee S.-H., Rho S.B. CYR61 controls p53 and NF-κB expression through PI3K/Akt/mTOR pathways in carboplatin-induced ovarian cancer cells. Cancer Lett. 2012, 315:86-95.
26. Liu A.M., Wong K.-F., Jiang X., Qiao Y., Luk J.M. Regulators of mammalian Hippo pathway in cancer. Biochim. Biophys. Acta 2012, 1826:357-364.
27. Liu-Chittenden Y., Huang B., Shim J.S., Chen Q., Lee S.-J., Anders R.A., Liu J.O., Pan D. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes. Dev. 2012, 26:1300-1305.
28. Marr B.P., Hung C., Gobin Y.P., Dunkel I.J., Brodie S.E., Abramson D.H. Success of intra-arterial chemotherapy (chemosurgery) for retinoblastoma: effect of orbitovascular anatomy. Arch. Ophthalmol. 2012, 130:180-185.
29. Miller J.W., Ursula S.-E., Michael S., Constantin P., Horst L., Irene B., Leonidas Z., Bertrand P., Guy D., Lane A.M., et al. Photodynamic therapy with verteporfinfor choroidal neovascularization caused by age-related macular degeneration. Arch. Ophthalmol. 1999, 117.
30. Mo J.S., Yu F.X., Gong R., Brown J.H., Guan K.L. Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs). Genes. Dev. 2012, 26:2138-2143.
31. Muen W.J., Kingston J.E., Robertson F., Brew S., Sagoo M.S., Reddy M.A. Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma. Ophthalmol. 2012, 119:611-616.
32. Munier F.L., Gaillard M.C., Balmer A., Soliman S., Podilsky G., Moulin A.P., Beck-Popovic M. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br. J. Ophthalmol. 2012, 96:1078-1083.
33. Nishimura S.S., Sato T.T., Ueda H.H., Ueda K.K. Acute myeloblastic leukemia as a second malignancy in a patient with hereditary retinoblastoma. J.Clin. Oncol. 2001, 19:4182-4183.
34. O'Bryan J.P., Frye R.A., Cogswell P.C., Neubauer A., Kitch B., Prokop C., Espinosa R., Le Beau M.M., Earp H.S., Liu E.T. Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Molec. Cell. Biol. 1991, 11:5016-5031.
35. Pal S.K., Quinn D.I. Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat. Rev. 2013, 39:709-719.
36. Pobbati A.V., Hong W. Emerging roles of TEAD transcription factors and its coactivators in cancers. Cancer Biol. Ther. 2013, 14:390-398.
37. Pogue B.W., OHara J.A., Demidenko E., Wilmot C.M., Goodwin I.A., Chen Bin, Swartz H.M., Hasan T. Photodynamic therapy with Verteporfin in the radiation-induced fibrosarcoma-1 tumor causes enhanced radiation sensitivity. Cancer Res. 2003, 1-9.
38. Prochownik E.V. c-Myc as a therapeutic target in cancer. Expert Rev. Anticancer Ther. 2004, 4(2):289-302.
39. Roarty J.D.J., McLean I.W.I., Zimmerman L.E.L. Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmol. 1988, 95:1583-1587.
40. Rodriguez-Galindo C.C., Wilson M.W.M., Haik B.G.B., Lipson M.J.M., Cain A.A., Merchant T.E.T., Kaste S.S., Pratt C.B.C. Treatment of metastatic retinoblastoma. Ophthalmol. 2003, 110:1237-1240.
41. Saini K.S., Loi S., de Azambuja E., Metzger-Filho O., Saini M.L., Ignatiadis M., Dancey J.E., Piccart-Gebhart M.J. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat. Rev. 2013, 39:935-946.
42. Sarbassov D.D., Ali S.M., Sabatini D.M. Growing roles for the mTOR pathway. Curr. Opin. Cell. Biol. 2005, 17:596-603.
43. Schefler A.C.A., Cicciarelli N.N., Feuer W.W., Toledano S.S., Murray T.G.T. Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Cord. Conf. Proc. 2007, 114:162-169.
44. Seigel G.M., Hackam A.S., Ganguly A., Mandell L.M., Gonzalez-Fernandez F. Human embryonic and neuronal stem cell markers in retinoblastoma. Mol. Vis. 2007 Jun 8, 13:823-832.
45. Sengupta T.K.T., Leclerc G.M.G., Hsieh-Kinser T.T.T., Leclerc G.J.G., Singh I.I., Barredo J.C.J. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol. Cancer 2007, 6. 46-46.
46. Shields C.L. Forget-me-nots in the care of children with retinoblastoma. Semin. Ophthalmol. 2009, 23:324-334.
47. Shields C.L.C., Honavar S.G.S., Shields J.A.J., Demirci H.H., Meadows A.T.A., Naduvilath T.J.T. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch. Ophthalmol. 2002, 120:460-464.
48. Shields C.L., Shelil A., Cater J., Meadows A.T., Shields J.A. Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients. Arch. Ophthalmol. 2003, 121:1571-1576.
49. Shields C.L., Palamar M., Sharma P., Ramasubramanian A., Leahey A., Meadows A.T., Shields J.A. Retinoblastoma regression patterns following chemoreduction and adjuvant therapy in 557 tumors. Arch. Ophthalmol. 2009, 127:282-290.
50. Shimomura T., Miyamura N., Hata S., Miura R., Hirayama J., Nishina H. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity. Biochem. Biophys. Res. Commun. 2014 Jan 17, 443(3):917-923.
51. Sussman D.A., Escalona-Benz E., Benz M.S., Hayden B.C., Feuer W., Cicciarelli N., Toledano S., Markoe A., Murray T.G. Comparison of retinoblastoma reduction for chemotherapy vs external beam radiotherapy. Arch. Ophthalmol. 2003, 121:979-984.
52. Tammela T., Saaristo A., Holopainen T., Ylä-Herttuala S., Andersson L.C., Virolainen S., Immonen I., Alitalo K. Photodynamic ablation of lymphatic vessels and intralymphatic cancer cells prevents metastasis. Sci Transl Med 2011, 3. 69ra11.
53. Teng A.C.T., Kuraitis D., Deeke S.A., Ahmadi A., Dugan S.G., Cheng B.L.M., Crowson M.G., Burgon P.G., Suuronen E.J., Chen H.H., et al. IRF2BP2 is a skeletal and cardiac muscle-enriched ischemia-inducible activator of VEGFA expression. Faseb J. 2010, 24:4825-4834.
54. Theodoropoulou S., Kolovou P.E., Morizane Y., Kayama M., Nicolaou F., Miller J.W., Evangeloss G., Ksander B.R., Vavvas D.G. Retinoblastoma cells are inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase. Faseb J. 2010, 24:2620-2630.
55. Theodoropoulou S., Brodowska K., Kayama M., Morizane Y., Miller J.W., Gragoudas E.S., Vavvas D.G. Aminoimidazole carboxamide ribonucleotide (AICAR) inhibits the growth of retinoblastoma invivo by decreasing angiogenesis and inducing apoptosis. PLoS ONE 2013, 8:e52852.
56. Tripursky M., Churgin D., Conway M., Peyman G. Areview of Photodynamic therapy for intraocular tumors. J.Anal. Bioanal. Tech. 2011, 01.
57. Trosko J.E. From adult stem cells to cancer stem cells: Oct-4 Gene, cell-cell communication, and hormones during tumor promotion. Ann. N. Y. Acad. Sci. 2006, 1089:36-58.
58. Tumaneng K., Schlegelmilch K., Russell R.C., Yimlamai D., Basnet H., Mahadevan N., Fitamant J., Bardeesy N., Camargo F.D., Guan K.-L. YAP mediates crosstalk between the hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nat. Cell. Biol. 2012, 14:1322-1329.
59. Vassilev A. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes. Dev. 2001, 15:1229-1241.
60. Xu M.Z., Chan S.W., Liu A.M., Wong K.F., Fan S.T., Chen J., Poon R.T., Zender L., Lowe S.W., Hong W., et al. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene 2011, 30:1229-1240.